Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colossolactone I is a naturally occurring triterpenoid isolated from the Vietnamese mushroom *Ganoderma colossum*. It is structurally characterized by a six-membered lactone ring (ring D) and belongs to a family of colossolactone compounds. Research presented at the AACR 2017 meeting evaluated its potential chemotherapeutic effects against various solid tumor cell lines, including breast (MCF-7), cervix (HeLa), colorectal (HCT-116), and liver (HepG2) cancers. In vitro studies demonstrated that colossolactone I possesses weak antioxidant activity and modest cytotoxic properties compared to other members of its class, such as colossolactone IV. It is primarily studied in an academic research context for its potential as a natural product-derived anticancer agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colossolactone I.